Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820669 | 0.94 | POLB (0.63) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| SCHEMBL17017 | 0.94 | POLB (0.63) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| SCHEMBL18760256 | 0.94 | POLB (0.63) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| Potassium SCHEMBL30906131 | 0.92 | POLB (0.61) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| SCHEMBL4082478 | 0.92 | POLB (0.61) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL1111003 | 0.92 | POLB (0.61) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| SCHEMBL22407731 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL22407717 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAPOLBSIGMAR1CA2 | |
| SCHEMBL5667296 | 0.89 | LMNA (0.57) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL25424462 | 0.87 | LMNA (0.55) | SMN1; SMN2LMNAPOLBGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802235-B2 | Drug and imaging agent delivery compositions and methods | UNIVERSITY OF KANSAS (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2013109907-A1 | DRUG AND IMAGING AGENT DELIVERY COMPOSITIONS AND METHODS | UNIVERSITY OF KANSAS (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20130189519-A1 | Drug and Imaging Agent Delivery Compositions and Methods | UNIVERSITY OF KANSAS (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2424843-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | Novartis AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| EP-2364303-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | disclosed |
| EP-1583757-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-10-12 | — | — | EP | disclosed |
| EP-1551830-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004026829-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-01 | — | — | WO | disclosed |
| EP-1175416-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000064885-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-02 | — | — | WO | disclosed |
| EP-1023285-A1 | AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999001451-A1 | AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | SMN1; SMN2 3941/4885LMNA 4233/4885POLB 1030/4885 |
| US-20130189519-A1 | Drug and Imaging Agent Delivery Compositions and Methods | STARD10, STARD7, CASP10 | SMN1; SMN2 4489/4885LMNA 3144/4885POLB 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.